Pharmaceutical profits to rise and food and beverage sales to decline amid GLP-1 drug expansion
LLY Lilly(Eli) & Co
$1179.27 +0.83%
View chart & analysis → - 1The use of GLP-1 injections among Americans has increased nearly fourfold since 2024.
- 2Combined sales of Eli Lilly's Mounjaro and Zepbound reached $36.5 billion in 2025.
- 3J.P. Morgan forecasts that GLP-1 treatments will reduce annual food and beverage industry sales by $30 billion to $55 billion from 2030 to 2034.
So what's the key point?
The use of weight-loss injections in the United States has increased fourfold. While Eli Lilly is expected to earn significant revenue, the food and beverage industry may see a decrease in sales.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.